ClinicalTrials.gg
Active, not recruitingNCT02715284GARNETUpdated Aug 25, 2026

Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors

A Phase 1 interventional study of Dostarlimab in Neoplasms, sponsored by Tesaro, Inc.. Active, not recruiting at 128 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-25.

Sponsored by Tesaro, Inc. (part of GlaxoSmithKline) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
729
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is a multi-center, open-label, first-in-human Phase 1 study evaluating the anti-programmed death receptor 1 (anti-PD-1) antibody dostarlimab (also known as TSR-042) n participants with advanced solid tumors who have limited available treatment options. The study will be conducted in 2 parts with Part 1 consisting of safety evaluation, pharmacokinetics (PK), and pharmacodynamics (PDy) of escalating doses of dostarlimab. Dose escalation will be based on ascending weight-based dose levels (DLs) of dostarlimab and will continue until the maximum tolerated dose (MTD) is reached or may be stopped at any dose level up to the highest dose of 20 milligrams per kilograms (mg/kg) based on emerging safety and PK/PDy data. Part 2 will be conducted in two subparts, Part 2A (fixed-dose safety evaluation cohorts) and Part 2B (expansion cohorts). Part 2A of the study will evaluate the safety and tolerability of dostarlimab at fixed doses of 500 mg administered every 3 weeks (Q3W) and 1000 mg administered every 6 weeks (Q6W). Part 2B of the study will examine the safety and clinical activity of dostarlimab in cohorts of participants with specific types of advanced solid tumors.

02

Conditions studied

  • Neoplasms

Keywords

  • Metastatic solid tumors
  • Advanced solid tumors
  • Anti-PD-1
  • TSR-042
  • Immunotherapy
  • PD-1
  • Endometrial
  • Non-small cell lung cancer
  • NSCLC
  • MSI-High
  • Dostarlimab
  • dMMR
03

In context

Neoplasms

10,826 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's enrollment of 729 is above the median of 60 across 7,707 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Tesaro, Inc. is the lead sponsor of 33 studies on the registry; none are open to participants now.

Of its 12 completed or terminated interventional studies of FDA-regulated products, 12 (100%) have results posted.

First submitted before Tesaro, Inc. became part of GlaxoSmithKline.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant is at least 18 years of age.
  • Participant has proven recurrent or advanced solid tumor and has disease progression after treatment with available anticancer therapies, or is intolerant to treatment that meets the following requirements for the part of the study they will participate in:

A. Part 1: Any or cytologically proven recurrent or advanced solid tumor B. Part 2A: : Any histologically or cytologically proven recurrent or advanced solid tumor

C. Part 2B: Histologically of cytologically proven recurrent or advanced solid tumor with (s) per version 1.1 and meets one of the following disease types:

The criteria below should be met for participant participating in: 1) Cohort A1 (dMMR/MSI-H endometrial cancer) and 2) Cohort A2 (MMR-proficient/MSS endometrial cancer)

  • Participants who have progressed on or after platinum doublet therapy
  • Participants have received no more than 2 lines of anticancer therapy for recurrent or advanced (>=Stage IIIB) disease. Prior treatment with hormone therapies is acceptable and does not count towards the number of anticancer therapies noted in the criterion above for this cohort.
  • All endometrial cancer histologies are allowed except endometrial sarcoma (including carcinosarcoma).
  • Participants must submit 2 scans demonstrating increase in tumor measurement that meet criteria for PD on or after the latest systemic anticancer therapy based on RECIST Version 1.1 to Central Radiology prior to the first dose of dostarlimab.
  • Presence of at least 1 measurable lesion on Baseline scan will be confirmed by central radiology review.
  • Status of tumor MMR/MSI: Participants can be screened based on local MMR/MSI testing results using immunohistochemistry (IHC), polymerase chain reaction (PCR), or next generation sequencing (NGS) performed in a certified local laboratory, but participant eligibility needs to be determined by MMR IHC results. For participant with available local MMR IHC results for the respective cohort(s), tumor samples have to be submitted to a central IHC laboratory and its quality has to be checked and cleared prior to Cycle 1 Day 1 (C1D1). For participants without available local MMR IHC test results (participants with local PCR or NGS test results), central IHC results have to confirm eligibility prior to proceeding with other screening procedures. After the central IHC test is completed, remaining tumor tissue may be tested for further exploratory biomarkers or may be sent to a central NGS laboratory for further testing.

    3) Cohort E - Participants with NSCLC who progressed after at least 1 prior platinum-based systemic chemotherapy regimen for recurrent or advanced disease.

  • Chemotherapy regimen in the or neoadjuvant setting following surgery and/or radiation is acceptable if recurrent or advanced disease develops within 6 months from completion of therapy.
  • Participants with a known epidermal growth factor receptor (EGFR) mutation must have received a chemotherapy regimen and an EGFR tyrosine kinase inhibitor (TKI) (e.g., erlotinib, gefitinib, afatinib, or experimental)
  • Participants with a known anaplastic lymphoma kinase (ALK) translocation must have received a chemotherapy regimen and an ALK inhibitor (e.g., crizotinib, ceritinib or experimental) 4) Cohort F - Participants with recurrent or advanced dMMR/MSI-H solid tumors except endometrial cancers and gastrointestinal cancers, who have received prior systemic therapy and who have no alternative treatment options. Prior treatment with hormone therapies alone given for recurrent or advanced disease is acceptable.
  • Presence of at least 1 measurable lesion by RECIST 1.1 on baseline scan will be confirmed by central radiology review prior to first dose of dostarlimab. Patients with primary central nervous system (CNS) tumor should provide brain MRI at baseline.
  • Presence of deficient mismatch repair (dMMR) and/or microsatellite instability (MSI-H) in the tumor defined by either:

    i) deficient DNA mismatch repair (dMMR); MMR status must be assessed by immunohistochemistry (IHC) for MMR protein expression (MLH1, MSH2, MSH6, PMS2) where loss of one or more proteins indicates dMMR; dMMR may be determined either locally or by the central reference lab; OR ii) Microsatellite instability (MSI-H); MSI-H as determined by polymerase chain reaction (PCR) or by tissue NGS; MSI-H may be determined locally 5) Cohort G: Participants must have recurrent high-grade serous, endometrioid, or clear cell ovarian, fallopian tube, or primary peritoneal cancer.

  • Participants must have presence of at least 1 measurable lesion on Baseline scan that will be confirmed by central radiology review.
  • Participants must be considered resistant to the last administered platinum therapy, that is, the time from the last administered platinum dose until the initial documented progression (as evidenced by radiographic progression per RECIST version 1.1) must be less than 6 months.
  • Participants must have completed at least 1 but no more than 3 for advanced or ovarian cancer. Neoadjuvant, adjuvant, and the combination of both will be considered as 1 line of therapy. Treatment with single-agent bevacizumab given as maintenance is not counted as a separate line of therapy. If a therapeutic regimen is modified or changed for a reason other than lack of response or PD (such as allergic reaction, toxicity, or drug availability), this is not counted as a separate line of therapy. The use of single-agent hormonal therapy given for reasons other than PD per RECIST version v1.1 (i.e., hormonal therapy given for increasing Cancer antigen [CA]-125 levels) is not counted as a separate line of therapy.
  • Participants must have been previously treated with platinum-based regimn, taxane agent(s), and bevacizumab (bevacizumab could be used as a single agent or in combination with another agent, in frontline therapy, as maintenance, or for treatment of recurrent disease).

    • Part 2B: Participants must have available that is formalin-fixed and paraffin-embedded (FFPE).
  • For participants who do not have archival tissue, a new biopsy must be performed to obtain a tissue sample prior to study treatment initiation. For participants without available archival tissue, the biopsy should be taken from the tumor lesions (either primary or metastatic) that have easy accessibility and low biopsy-associated risks and will exclude biopsies of the liver, brain, lung/mediastinum, pancreas, or endoscopic procedures extending beyond the esophagus, stomach or bowel.
  • For Cohort F an FFPE tissue sample must be submitted to the central laboratory for testing. Specimens containing bone are not acceptable. For patients with available local MMR/MSI-H results, tumor samples have to be submitted to a central laboratory and its quality has to be checked and cleared prior to C1D1
  • For Cohort G, participant must provide formalin fixed paraffin embedded (FFPE) tumor tissue block(s) with sufficient tumor content (as confirmed by the Sponsor's designated central laboratory) during screening to enable, for example, measures of homologous recombination pathway defects and status. The use of slides created from paraffin-embedded tissue as opposed to FFPE blocks must be approved by the Sponsor.

    • Female participants must have a negative serum pregnancy test within 72 hours prior to the date of the first dose of study medication: unless they are of non-child bearing potential.Non child bearing potential is defined as:
  • >= 45 years of age and has not had menses for > 1 year;
  • Amenorrheic for \< 2 years without a hysterectomy and oophorectomy and have a follicle- stimulating hormone (FSH) value in the range upon pre-study (screening) evaluation.
  • Post-hysterectomy, post-bilateral oophorectomy, or post-tubal ligation. Documented hysterectomy or oophorectomy must be confirmed with medical records of the actual procedure or confirmed by an ultrasound, magnetic resonance imaging (MRI) or computed tomography (CT) scan. Tubal ligation must be confirmed with medical records of the actual procedure.

    • Female participants of must agree to use 1 highly effective form of with their partner starting with the screening visit through 150 days after the last dose of study therapy.
    • Participant has an (ECOG) performance status of \<= 2 for Part 1 and \<= 1 for Part 2.
    • Participant has an adequate organ function.
    • Participants with known (HIV) infection are allowed with following requirements:
  • Documented evidence of plasma HIV-1 RNA persistently \<50 copies (c)/mL ≤3 months prior to AND at Screening. In the >3 to 12 months prior to Screening, plasma HIV-1 RNA consistently \<50 c/mL required; if single increases ≥50 c/mL occurred, they cannot have been persistent nor associated with antiretroviral resistance per Investigator's assessment AND
  • >350 cells/mm\^3 over past 12 months and at Screening (and no measurement ≤200 cells/mm3 during that time period) AND
  • Must be on an uninterrupted combination antiretroviral therapy regimen for at least 3 months prior to Screening, with combination antiretroviral therapy regimen consistent with locally recommended guidelines

    • Participants with history of Centers for Disease Control and Prevention (CDC) Stage 3 disease (CDC, 2014; also known as acquired immunodeficiency syndrome [AIDS]- defining disease) are allowed if AIDS-defining disease has been treated and cured or is stable for ≥3 months prior to study entry. Cutaneous Kaposi's Sarcoma not requiring systemic therapy is allowed.
    • No history of HIV-associated non-Hodgkin lymphoma ≤5 years prior to study and no history of HIV-associated invasive cervical cancer
    • No treatment with an HIV-1 immunotherapeutic vaccine within 90 days of Screening.

Exclusion criteria

Exclusion Criteria:

  • Participant has received prior therapy with an anti- programmed death receptor 1 (), anti-PD-1- ligand-1 (anti-PD-L1), or anti-PD-1 ligand-2 (anti-PD- L2) agent.
  • Participant has a known uncontrolled and/or carcinomatous meningitis.
  • Participant has a known additional that progressed or required active treatment within the last 2 years. Exceptions include basal cell carcinoma of the skin, squamous cell cancer (SqCC) of the skin that has undergone potentially curative therapy, or in situ cervical cancer, or other neoplastic condition which has undergone curative therapy and is considered cured by the investigator.
  • Participant is considered a poor medical risk due to a serious, uncontrolled medical disorder, nonmalignant systemic disease or active infection requiring systemic therapy. Specific examples include, but are not limited to, active, non-infectious pneumonitis; uncontrolled ventricular arrhythmia; recent (within 90 days) myocardial infarction; uncontrolled major seizure disorder; unstable spinal cord compression; superior vena cava syndrome; or any psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the study (including obtaining ).
  • Participant is pregnant or breastfeeding or expecting to conceive children within the projected duration of the study, starting with the Screening Visit through 150 days after the last dose of study treatment.
  • Participant has a diagnosis of immunodeficiency or is receiving systemic therapy or any other form of therapy within 7 days prior to the first dose of study treatment.
  • Participant has a documented presence of surface antigen [HBsAg] at screening or within 3 months prior to the first dose of study intervention. Participants with a negative HbsAg and positive hepatitis B virus core antibody (HBcAb) result are eligible only if HBV DNA is negative.
  • Participant has an active disease that has required systemic treatment in the past 2 years (i.e., with use of disease- modifying agents, corticosteroids, or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment. Use of inhaled steroids, local injection of steroids, and steroid eye drops are allowed.
  • Participant has as history of interstitial lung disease.
  • Participant has not recovered (i.e., to \<= Grade 1 or to Baseline) from radiation- and chemotherapy-induced AEs or received transfusion of blood products (including or red blood cells) or administration of colony-stimulating factors (including granulocyte-colony stimulating factor [G-CSF], granulocyte macrophage colony-stimulating factor [GM-CSF] or recombinant erythropoietin) within 3 weeks prior to the first dose of study drug.
  • Participant has participated in a study of an agent and received study therapy or used an investigational device within 4 weeks prior to the first dose of study drug.
  • Participant has received prior anticancer therapy (chemotherapy, targeted therapies, radiotherapy, or immunotherapy) within 21 days prior to study Day 1
  • Participant has not recovered adequately (\<= Grade 1) from AEs and/or complications from any major surgery prior to starting therapy.
  • Participant has received a within 14 days of planned start of study therapy.
  • Participant has a known to dostarlimab components or .
  • For Cohort G, participants will not be eligible if they meet the following criteria:

    • Participants who experienced disease progression within 3 months (as evidenced by radiographic progression per ) of platinum therapy.
    • Participants with known deleterious or suspicious deleterious mutation in BRCA1 or BRCA2 genes (local testing permitted).
    • Participants has received prior therapy with a poly(adenosine diphosphate-ribose) polymerase (PARP)-1/PARP-2 inhibitor.
    • Participant has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, might interfere with the participant's participation for the full duration of the study treatment, or is not in the best interest of the participant to participate.
    • Participant is immunocompromised. Participants with splenectomy are allowed.
Terms in these criteria, in plain language(26)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
729 participants (actual)

Study arms

  • Experimental
    Part 1: Participants receiving dostarlimab

    Part 1 will evaluate dostarlimab at ascending weight-based doses 1 mg/kg, 3 mg/kg and 10 mg/kg. Higher dose levels 15 mg/kg and/or 20 mg/kg may also be explored. Dostarlimab will be administered intravenously (IV) on Day 1 and Day 15 of each cycle; cycle length is 28 days. Cohorts will be enrolled sequentially and will initially follow a 3+3 design.

    Biological: Dostarlimab

  • Experimental
    Part 2A: Participants receiving dostarlimab

    In Part 2A, participants will receive fixed dose of 500 mg administered Q3W or 1000 mg administered Q6W dose on Day 1 of each cycle. Cycle duration for Q3W dosing is 21 days and Q6W dosing is 42 days. Cohorts will enroll participants with advanced solid tumor using a modified 6+6 design and will follow a 6+6 design.

    Biological: Dostarlimab

  • Experimental
    Part 2B: Cohort A1 dMMR/MSI-H endometrial cancer

    Part 2B: Cohort A1 will include participants with mismatch repair deficient microsatellite instability high (dMMR/MSI-H) endometrial cancer who have progressed on or after platinum doublet therapy. These participants will receive dostarlimab 500 mg for Q3W for the first 4 cycles followed by 1000 mg Q6W for all subsequent cycles. Participants have received no more than 2 lines of anti-cancer therapy for recurrent or advanced (Stage \>= IIIB) disease.

    Biological: Dostarlimab

  • Experimental
    Part 2B: Cohort A2 MMR-proficient/MSS endometrial cancer

    Part 2B: Cohort A2 will include participants with MMR-proficient/MSS endometrial cancer who have progressed on or after platinum doublet therapy. These participants will receive dostarlimab 500 mg for Q3W for the first 4 cycles followed by 1000 mg Q6W for all subsequent cycles. Participants have received no more than 2 lines of anti-cancer therapy for recurrent or advanced (Stage \>=IIIB) disease.

    Biological: Dostarlimab

  • Experimental
    Part 2B: Cohort E NSCLC

    Part 2B: Cohort E NSCLC will include participants with non-small cell lung cancer (NSCLC) who progressed after at least 1 prior platinum-based systemic chemotherapy regimen for recurrent or advanced disease. These participants will receive dostarlimab 500 mg for Q3W for the first 4 cycles followed by 1000 mg Q6W for all subsequent cycles.

    Biological: Dostarlimab

  • Experimental
    Part 2B: Cohort F non-endometrial dMMR/MSI-H or POLE-Mut cancers

    Participants with recurrent or advanced dMMR/MSI-H solid tumors except endometrial cancers, and gastrointestinal cancers, who have received prior systemic therapy and, who have no alternative treatment options. These participants will receive dostarlimab 500 mg for Q3W for the first 4 cycles followed by 1000 mg Q6W for all subsequent cycles.

    Biological: Dostarlimab

  • Experimental
    Part 2B: Cohort G PROC without known BRCA

    Participants with advanced, relapsed, high-grade serous, endometrioid, or clear cell ovarian, fallopian tube, or primary peritoneal cancer without known breast cancer susceptibility gene (BRCA) mutation who have platinum-resistant disease receiving dostarlimab and who have also been previously treated with bevacizumab. These participants will receive dostarlimab 500 mg for Q3W for the first 4 cycles followed by 1000 mg Q6W for all subsequent cycles.

    Biological: Dostarlimab

Interventions

  • BiologicalDostarlimab

    Dostarlimab (160 mg, 20 mg/mL; or 500 mg, 50 mg/mL) is a humanized monoclonal antibody that binds with high affinity to PD-1 resulting in inhibition of binding to programmed death receptor ligands 1 and 2 (PD-L1 and PD-L2). Dostarlimab will be administered via a 30 minute IV infusion on Day 1 and Day 15 of each cycle in Part 1. For additional patients enrolled specifically to better characterize the PK/PDy profile in Part 1, dostarlimab administration during Cycle 1 will only occur on Day 1 with the second dose administered on Cycle 2/Day 1 and Q2W thereafter. For Part 2A and 2B, dostarlimab will be administered on Day 1 of each treatment cycle. Cycle duration for Q3W dosing is 21 days and Q6W dosing is 42 days.

06

What researchers measure

Primary outcomes

  1. Part 1: Number of participants with treatment emergent AEs (TEAEs)

    An adverse event (AE) is any untoward medical occurrence that occurs in a participant or clinical investigation participant administered a pharmaceutical product, and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including clinically significant abnormal laboratory findings), symptom, or disease temporally associated with the use of an investigational product, whether or not considered related to the product. TEAEs defined as any AE either reported for the first time or worsening of a pre-existing event after first dose of study treatment.

    Time frame: Up to 2 years

  2. Part 1: Number of participants with immune mediated AEs of interest

    Participants with immune related AEs of interest will be assessed.

    Time frame: Up to 2 years

  3. Part 1: Number of participants with abnormal hematology parameters

    Blood samples will be collected to assess the following hematology parameters: hemoglobin, Mean corpuscular (MCV), white blood cell count (WBC count), platelets, mean platelet volume, differential WBC count and coagulation factors including International normalized ratio (INR), activated partial thromboplastin time (aPTT) and prothrombin time (PT).

    Time frame: Up to 2 years

  4. Part 1: Number of participants with abnormal clinical chemistry parameters

    Blood samples will be collected to assess the following chemistry parameters: sodium, potassium, calcium, magnesium, creatinine, bilirubin, alkaline phosphatase, aspartate aminotransferase (AST), alanine aminotransferase (ALT), and albumin.

    Time frame: Up to 2 years

  5. Part 1, Part 2A, and Part 2B: Number of participants with a change from baseline in urinalysis parameters

    Number of participants will be assessed.

    Time frame: Up to 2 years

  6. Part 1, Part 2A, and Part 2B: Number of participants with a change from baseline in vital signs

    Number of participants will be assessed.

    Time frame: Up to 2 years

  7. Part 1: Number of participants with abnormal electrocardiogram (ECG) parameters

    Participants will be supine or in a semi-recumbent position and rested for approximately 2 minutes before ECGs are recorded.

    Time frame: Up to 2 years

  8. Part 1: Number of participants receiving concomitant medications

    Concomitant medications will be recorded.

    Time frame: Up to 2 years

  9. Part 2A: Number of participants with TEAEs

    An AE is any untoward medical occurrence that occurs in a participant or clinical investigation participant administered a pharmaceutical product, and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including clinically significant abnormal laboratory findings), symptom, or disease temporally associated with the use of an investigational product, whether or not considered related to the product. TEAEs defined as any AE either reported for the first dose of study treatment.

    Time frame: Up to 2 years

  10. Part 2A: Number of participants with immune mediated AEs of interest

    Participants with immune related AEs of interest will be assessed.

    Time frame: Up to 2 years

  11. Part 2A: Number of participants with abnormal hematology parameters

    Blood samples will be collected to assess the following hematology parameters: hemoglobin, MCV, white WBC count, platelets, mean platelet volume, differential WBC count and coagulation factors including INR, aPTT and PT.

    Time frame: Up to 2 years

  12. Part 2A: Number of participants with abnormal clinical chemistry parameters

    Blood samples will be collected to assess the following chemistry parameters: sodium, potassium, calcium, magnesium, creatinine, bilirubin, AST, ALT, and albumin.

    Time frame: Up to 2 years

  13. Part 2A: Number of participants with abnormal ECG

    Participants will be supine or in a semi-recumbent position and rested for approximately 2 minutes before ECGs are recorded.

    Time frame: Up to 2 years

  14. Part 2A: Number of participants receiving concomitant medications

    Concomitant medications will be recorded.

    Time frame: Up to 2 years

  15. Part 2B: Number of participants with TEAEs

    An AE is any untoward medical occurrence that occurs in a participant or clinical investigation participant administered a pharmaceutical product, and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including clinically significant abnormal laboratory findings), symptom, or disease temporally associated with the use of an investigational product, whether or not considered related to the product. TEAEs defined as any AE either reported for the first dose of study treatment.

    Time frame: Up to 2 years

  16. Part 2B: Number of participants with immune related AEs of interest

    Participants with immune related AEs of interest will be assessed.

    Time frame: Up to 2 years

  17. Part 2B: Number of participants with abnormal hematology parameters

    Blood samples will be collected to assess the following hematology parameters: hemoglobin, MCV, white WBC count, platelets, mean platelet volume, differential WBC count and coagulation factors including INR, aPTT and PT.

    Time frame: Up to 2 years

  18. Part 2B: Number of participants with abnormal clinical chemistry parameters

    Blood samples will be collected to assess the following chemistry parameters: sodium, potassium, calcium, magnesium, creatinine, bilirubin, AST, ALT, and albumin.

    Time frame: Up to 2 years

  19. Part 2B: Number of participants with abnormal ECG parameters

    Participants will be supine or in a semi-recumbent position and rested for approximately 2 minutes before ECGs are recorded.

    Time frame: Up to 2 years

  20. Part 2B: Number of participants receiving concomitant medications

    Concomitant medications will be recorded.

    Time frame: Up to 2 years

  21. Part 2B: Cohort A1 Overall Response Rate (ORR) by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1

    ORR is defined as the proportion of participants achieving complete response (CR) or partial response (PR) as evaluated by independent blinded central review using RECIST version 1.1.

    Time frame: Up to 2 years

  22. Part 2B: Cohort F ORR by RECIST version 1.1

    ORR is defined as the proportion of participants achieving CR or PR as evaluated by independent blinded central review using RECIST version 1.1.

    Time frame: Up to 2 years

  23. Part 2B: Cohort A2 ORR by RECIST version 1.1

    ORR is defined as the proportion of participants achieving CR or PR as evaluated by independent blinded central review using RECIST version 1.1.

    Time frame: Up to 2 years

  24. Part 2B: Cohort G ORR by RECIST version 1.1

    ORR is defined as the proportion of participants achieving CR or PR as evaluated by independent blinded central review using RECIST version 1.1.

    Time frame: Up to 2 years

  25. Part 2B: Cohort E ORR by immune related Response Evaluation Criteria in Solid Tumors per irRECIST

    ORR is defined as the proportion of participants achieving CR or PR as assessed by investigator per irRECIST will be evaluated.

    Time frame: Up to 2 years

  26. Part 2B: Cohort A1 Duration of response (DOR)

    DOR is defined as the time from first documentation of CR or PR by RECIST version 1.1 until the time of first documentation of progressive disease (PD) evaluated using RECIST version 1.1 based on independent blinded central review, or death due to any cause.

    Time frame: Up to 2 years

  27. Part 2B: Cohort F Duration of response (DOR)

    DOR is defined as the time from first documentation of CR or PR by RECIST version 1.1 until the time of first documentation of PD evaluated using RECIST version 1.1 based on independent blinded central review, or death due to any cause.

    Time frame: Up to 2 years

  28. Part 2B: Cohort A2 Duration of response (DOR)

    DOR is defined as the time from first documentation of CR or PR by RECIST version 1.1 until the time of first documentation of PD evaluated using RECIST version 1.1 based on independent blinded central review, or death due to any cause.

    Time frame: Up to 2 years

Secondary outcomes

  1. Part 1: Immune-related objective response rate (irORR) by irRECIST

    Immune-related objective response rate will be evaluated based on investigator's assessment using irRECIST.

    Time frame: Up to 2 years

  2. Part 2B: Cohort A1 ORR by independent blinded central review using RECIST version 1.1

    ORR is defined as the proportion of participants achieving CR or PR as evaluated by independent blinded central review using RECIST version 1.1.

    Time frame: Up to 2 years

  3. Part 2B: Cohort F ORR by independent blinded central review using RECIST version 1.1

    ORR is defined as the proportion of participants achieving CR or PR as evaluated by independent blinded central review using RECIST version 1.1.

    Time frame: Up to 2 years

  4. Part 2B: Cohort A1 Immune-related objective response rate (irORR) by irRECIST

    Immune related objective response rate will be evaluated based on investigator's assessment using irRECIST.

    Time frame: Up to 2 years

  5. Part 2B: Cohort A2 irORR by irRECIST

    Immune related objective response rate will be evaluated based on investigator's assessment using irRECIST.

    Time frame: Up to 2 years

  6. Part 2B: Cohort F irORR by irRECIST

    Immune related objective response rate will be evaluated based on investigator's assessment using irRECIST.

    Time frame: Up to 2 years

  7. Part 2B: Cohort G irORR by irRECIST

    Immune related objective response rate will be evaluated based on investigator's assessment using irRECIST.

    Time frame: Up to 2 years

  8. Part 2B: Cohort A1 Duration of response (DOR) based on independent blinded central review using RECIST version 1.1

    DOR is defined as the time from first documentation of CR or PR by RECIST version 1.1 until the time of first documentation of progressive disease (PD) evaluated using RECIST version 1.1 based on independent blinded central review, or death due to any cause.

    Time frame: Up to 2 years

  9. Part 2B: Cohort F DOR based on independent blinded central review using RECIST version 1.1

    DOR is defined as the time from first documentation of CR or PR by RECIST version 1.1 until the time of first documentation of PD evaluated using RECIST version 1.1 based on independent blinded central review, or death due to any cause.

    Time frame: Up to 2 years

  10. Part 2B: Cohort G DOR based on independent blinded central review using RECIST version 1.1

    DOR is defined as the time from first documentation of CR or PR by RECIST version 1.1 until the time of first documentation of PD evaluated using RECIST version 1.1 based on independent blinded central review, or death due to any cause.

    Time frame: Up to 2 years

  11. Part 2B: Cohort A1 Disease control rate

    Disease control rate is the proportion of participants achieving CR, PR, or SD per RECIST v1.1 based on independent blinded central review.

    Time frame: Up to 2 years

  12. Part 2B: Cohort A2 Disease control rate

    Disease control rate is the proportion of participants achieving CR, PR, or SD per RECIST v1.1 based on independent blinded central review.

    Time frame: Up to 2 years

  13. Part 2B: Cohort F Disease control rate

    Disease control rate is the proportion of participants achieving CR, PR, or SD per RECIST v1.1 based on independent blinded central review.

    Time frame: Up to 2 years

  14. Part 2B: Cohort G Disease control rate

    Disease control rate is the proportion of participants achieving CR, PR, or SD per RECIST v1.1 based on independent blinded central review.

    Time frame: Up to 2 years

  15. Immune related disease control rate

    The proportion of participants achieving CR, PR, or SD per irRECIST based on Investigators assessment.

    Time frame: Up to 2 years

  16. Immune related duration of response

    The time from first documentation of CR or PR by irRECIST until the time of first documentation of PD (subsequently confirmed) per irRECIST based on Investigators assessment.

    Time frame: Up to 2 years

  17. Progression free survival

    The time from date of first dose to the earlier date of assessment of progression or death by any cause in the absence of progression based on: (1) the time of first documentation of PD per RECIST v1.1 (for Cohorts A1, A2, F, and G only); and (2) the time of first documentation of PD (subsequently confirmed) per irRECIST.

    Time frame: Up to 2 years

  18. Overall survival

    The time from date of first dose of study treatment to the date of death by any cause.

    Time frame: Up to 2 years

  19. Part 1: Area under the concentration-time curve from time 0 to last (AUC,0-last) assessment of dostarlimab

    Blood samples for determination of serum levels of dostarlimab will be collected.

    Time frame: Predose, 0.25, 0.5, 1.5, 3, 24, 48, 96, 168, 336, 504 and 672 hours post dose

  20. Part 1: Area under the concentration-time curve from time 0 to infinity (AUC, 0-infinity) of dostarlimab

    Blood samples for determination of serum levels of dostarlimab will be collected.

    Time frame: Predose, 0.25, 0.5, 1.5, 3, 24, 48, 96, 168, 336, 504, 672 hours post dose

  21. Part 1: Minimum concentration (Cmin) of dostarlimab

    Blood samples for determination of serum levels of dostarlimab will be collected.

    Time frame: Predose, 0.25, 0.5, 1.5, 3, 24, 48, 96, 168, 336, 504, 672 hours post dose

  22. Part 1: Maximum concentration (Cmax) of dostarlimab

    Blood samples for determination of serum levels of dostarlimab will be collected.

    Time frame: Predose, 0.25, 0.5, 1.5, 3, 24, 48, 96, 168, 336, 504, 672 hours post dose

  23. Part 1: Clearance (CL) of dostarlimab

    Blood samples for determination of serum levels of dostarlimab will be collected.

    Time frame: Predose, 0.25, 0.5, 1.5, 3, 24, 48, 96, 168, 336, 504, 672 hours post dose

  24. Part 1: Volume of distribution (Vz) of dostarlimab

    Blood samples for determination of serum levels of dostarlimab will be collected.

    Time frame: Predose, 0.25, 0.5, 1.5, 3, 24, 48, 96, 168, 336, 504, 672 hours post dose

  25. Part 1: Area under the concentration-time curve at steady state (AUC,ss) of dostarlimab

    Blood samples for determination of serum levels of dostarlimab will be collected.

    Time frame: Predose, 0.25, 0.5, 1.5, 3, 24, 48, 96, 168, 336, 504, 672 hours post dose

  26. Part 1: Minimum concentration at steady state (Cmin,ss) of dostarlimab

    Blood samples for determination of serum levels of dostarlimab will be collected.

    Time frame: Predose, 0.25, 0.5, 1.5, 3, 24, 48, 96, 168, 336, 504,672 hours post dose.

  27. Part 1: Maximum concentration at steady state (Cmax,ss) of dostarlimab

    Blood samples for determination of serum levels of dostarlimab will be collected.

    Time frame: Predose, 0.25, 0.5, 1.5, 3, 24, 48, 96, 168, 336, 504, 672 hours post dose

  28. Part 2A: AUC,0-last assessment of dostarlimab

    Blood samples for determination of serum levels of dostarlimab will be collected.

    Time frame: Predose, 0.25, 0.5, 1.5, 3, 24, 48, 96, 168, 336, and 504 hours post dose Q3W upto 2 years

  29. Part 2A: AUC, 0-infinity of dostarlimab

    Blood samples for determination of serum levels of dostarlimab will be collected.

    Time frame: Predose, 0.25, 0.5, 1.5, 3, 24, 48, 96, 168, 336, and 504 hours post dose Q3W upto 2 years

  30. Part 2A: Cmin of dostarlimab

    Blood samples for determination of serum levels of dostarlimab will be collected

    Time frame: Predose, 0.25, 0.5, 1.5, 3, 24, 48, 96, 168, 336, and 504,hours post dose Q3W upto 2 years

  31. Part 2A: Cmax of dostarlimab

    Blood samples for determination of serum levels of dostarlimab will be collected.

    Time frame: Predose, 0.25, 0.5, 1.5, 3, 24, 48, 96, 168, 336, and 504,hours post dose Q3W upto 2 years

  32. Part 2A: CL of dostarlimab

    Blood samples for determination of serum levels of dostarlimab will be collected.

    Time frame: Predose, 0.25, 0.5, 1.5, 3, 24, 48, 96, 168, 336, and 504,hours post dose Q3W upto 2 years

  33. Part 2A: Vz of dostarlimab

    Blood samples for determination of serum levels of dostarlimab will be collected.

    Time frame: Predose, 0.25, 0.5, 1.5, 3, 24, 48, 96, 168, 336, and 504 hours post dose Q3W upto 2 years.

  34. Part 2A: AUC,ss of dostarlimab

    Blood samples for determination of serum levels of dostarlimab will be collected.

    Time frame: Predose, 0.25, 0.5, 1.5, 3, 24, 48, 96, 168, 336, and 504 hours post dose Q3W upto 2 years

  35. Part 2A: Cmin,ss of dostarlimab

    Blood samples for determination of serum levels of dostarlimab will be collected.

    Time frame: Predose, 0.25, 0.5, 1.5, 3, 24, 48, 96, 168, 336, and 504 hours post dose Q3W upto 2 years

  36. Part 2A: Cmax,ss of dostarlimab

    Blood samples for determination of serum levels of dostarlimab will be collected.

    Time frame: Predose, 0.25, 0.5, 1.5, 3, 24, 48, 96, 168, 336, and 504 hours post dose Q3W upto 2 years

  37. Part 2A : AUC,0-last assessment of dostarlimab

    Blood samples for determination of serum levels of dostarlimab will be collected.

    Time frame: Predose, 0.25, 0.5, 1.5, 3, 24, 48, 96, 168, 336, 504, 672, 840, and 1008 hours post dose Q6W upto 2 years

  38. Part 2A: AUC, 0-infinity of dostarlimab

    Blood samples for determination of serum levels of dostarlimab will be collected.

    Time frame: Predose, 0.25, 0.5, 1.5, 3, 24, 48, 96, 168, 336, 504, 672, 840, and 1008 hours post dose Q6W upto 2 years

  39. Part 2A: Cmin of dostarlimab

    Blood samples for determination of serum levels of dostarlimab will be collected.

    Time frame: Predose, 0.25, 0.5, 1.5, 3, 24, 48, 96, 168, 336, 504, 672, 840, and 1008 hours post dose Q6W upto 2 years

  40. Part 2A: Cmax of dostarlimab

    Blood samples for determination of serum levels of dostarlimab will be collected.

    Time frame: Predose, 0.25, 0.5, 1.5, 3, 24, 48, 96, 168, 336, 504, 672, 840, and 1008 hours post dose Q6W upto 2 years

  41. Part 2A: CL of dostarlimab

    Blood samples for determination of serum levels of dostarlimab will be collected.

    Time frame: Predose, 0.25, 0.5, 1.5, 3, 24, 48, 96, 168, 336, 504, 672, 840, and 1008 hours post dose Q6W upto 2 years

  42. Part 2A: Vz of dostarlimab

    Blood samples for determination of serum levels of dostarlimab will be collected.

    Time frame: Predose, 0.25, 0.5, 1.5, 3, 24, 48, 96, 168, 336, 504, 672, 840, and 1008 hours post dose Q6W upto 2 years

  43. Part 2A: AUC,ss of dostarlimab

    Blood samples for determination of serum levels of dostarlimab will be collected.

    Time frame: Predose, 0.25, 0.5, 1.5, 3, 24, 48, 96, 168, 336, 504, 672, 840, and 1008 hours post dose Q6W upto 2 years

  44. Part 2A: Cmin,ss of dostarlimab

    Blood samples for determination of serum levels of dostarlimab will be collected.

    Time frame: Predose, 0.25, 0.5, 1.5, 3, 24, 48, 96, 168, 336, 504, 672, 840, and 1008 hours post dose Q6W upto 2 years

  45. Part 2A: Cmax,ss of dostarlimab

    Blood samples for determination of serum levels of dostarlimab will be collected.

    Time frame: Predose, 0.25, 0.5, 1.5, 3, 24, 48, 96, 168, 336, 504, 672, 840 and 1008 hours post dose Q6W upto 2 years

  46. Part 2B: Cmax of dostarlimab

    Blood samples for determination of serum levels of dostarlimab will be collected.

    Time frame: Predose, 0.5 and 1.5 hours post dose

  47. Part 2B: AUC,ss of dostarlimab

    Blood samples for determination of serum levels of dostarlimab will be collected.

    Time frame: Predose, 0.5 and 1.5 hours post dose

  48. Part 2B: Cmax,ss of dostarlimab

    Blood samples for determination of serum levels of dostarlimab will be collected.

    Time frame: Predose, 0.5 and 1.5 hours post dose

  49. Part 1, Part 2A, and Part 2B: Number of participants with antidrug antibodies (ADA) against dostarlimab

    Time frame: Up to 2 years

07

Study locations

128 sites
  • GSK Investigational Site
    Birmingham, Alabama 35233, United States
  • GSK Investigational Site
    Goodyear, Arizona 85338, United States
  • GSK Investigational Site
    Scottsdale, Arizona 85258, United States
  • GSK Investigational Site
    Fayetteville, Arkansas 72703, United States
  • GSK Investigational Site
    Encinitas, California 92024, United States
  • GSK Investigational Site
    La Jolla, California 92093, United States
  • GSK Investigational Site
    Los Angeles, California 90095, United States
  • GSK Investigational Site
    Newport Beach, California 92663, United States
  • GSK Investigational Site
    San Francisco, California 94115, United States
  • GSK Investigational Site
    San Marcos, California 92069, United States
  • GSK Investigational Site
    Santa Monica, California 90403, United States
  • GSK Investigational Site
    Washington D.C., District of Columbia 20007, United States
  • GSK Investigational Site
    Miami, Florida 33136, United States
  • GSK Investigational Site
    Tampa, Florida 33612, United States
  • GSK Investigational Site
    Augusta, Georgia 30912, United States
  • GSK Investigational Site
    Chicago, Illinois 60637, United States
  • GSK Investigational Site
    Fairway, Kansas 66205, United States
  • GSK Investigational Site
    Scarborough, Maine 04074, United States
  • GSK Investigational Site
    Baltimore, Maryland 21231, United States
  • GSK Investigational Site
    Boston, Massachusetts 02114, United States
  • GSK Investigational Site
    Boston, Massachusetts 02215, United States
  • GSK Investigational Site
    Detroit, Michigan 48201, United States
  • GSK Investigational Site
    Kansas City, Missouri 64111, United States
  • GSK Investigational Site
    Farmington, New Mexico 87401, United States
  • GSK Investigational Site
    Albany, New York 12208, United States
  • GSK Investigational Site
    Brooklyn, New York 11203, United States
  • GSK Investigational Site
    Jamaica, New York 11432, United States
  • GSK Investigational Site
    New York, New York 10016, United States
  • GSK Investigational Site
    Charlotte, North Carolina 28204, United States
  • GSK Investigational Site
    Cleveland, Ohio 44106, United States
  • GSK Investigational Site
    Columbus, Ohio 43210, United States
  • GSK Investigational Site
    Hilliard, Ohio 43026, United States
  • GSK Investigational Site
    Hilliard, Ohio 43210, United States
  • GSK Investigational Site
    Oklahoma City, Oklahoma 73104, United States
  • GSK Investigational Site
    Philadelphia, Pennsylvania 19104, United States
  • GSK Investigational Site
    Philadelphia, Pennsylvania 19111, United States
  • GSK Investigational Site
    Providence, Rhode Island 02905, United States
  • GSK Investigational Site
    Dallas, Texas 75230, United States
  • GSK Investigational Site
    Dallas, Texas 75290-9032, United States
  • GSK Investigational Site
    San Antonio, Texas 78229-3307, United States
  • GSK Investigational Site
    San Antonio, Texas 78229, United States
  • GSK Investigational Site
    Salt Lake City, Utah 84112, United States
  • GSK Investigational Site
    Charlottesville, Virginia 22903, United States
  • GSK Investigational Site
    Seattle, Washington 98104, United States
  • GSK Investigational Site
    Seattle, Washington 98195, United States
  • GSK Investigational Site
    Spokane, Washington 99202, United States
  • GSK Investigational Site
    Spokane, Washington 99204, United States
  • GSK Investigational Site
    Milwaukee, Wisconsin 53226, United States
  • GSK Investigational Site
    Ciudad Autonoma de Buenos Aire, C1280AEB, Argentina
  • GSK Investigational Site
    Córdoba, X5000HXL, Argentina
  • GSK Investigational Site
    Córdoba, X5004FHP, Argentina
  • GSK Investigational Site
    Barretos, 14784-400, Brazil
  • GSK Investigational Site
    Porto Alegre, 90035-000, Brazil
  • GSK Investigational Site
    Ribeirão Preto, 14040-030, Brazil
  • GSK Investigational Site
    Rio de Janeiro, 20231-050, Brazil
  • GSK Investigational Site
    São José do Rio Preto, 15090-200, Brazil
  • GSK Investigational Site
    São Paulo, 01246-000, Brazil
  • GSK Investigational Site
    São Paulo, 01308-500, Brazil
  • GSK Investigational Site
    São Paulo, 01321-001, Brazil
  • GSK Investigational Site
    Calgary, Alberta T2N 4N2, Canada
  • GSK Investigational Site
    Edmonton, Alberta T6G 1Z2, Canada
  • GSK Investigational Site
    Kelowna, British Columbia V1Y 5L3, Canada
  • GSK Investigational Site
    Vancouver, British Columbia V5Z 4E6, Canada
  • GSK Investigational Site
    Hamilton, Ontario L8V 5C2, Canada
  • GSK Investigational Site
    London, Ontario N6A 4L6, Canada
  • GSK Investigational Site
    Toronto, Ontario M5G 2M9, Canada
  • GSK Investigational Site
    Montreal, Quebec H2L 4M1, Canada
  • GSK Investigational Site
    Montreal, Quebec H4A 3J1, Canada
  • GSK Investigational Site
    Hořovice, 26831, Czechia
  • GSK Investigational Site
    Zlín, 762 75, Czechia
  • GSK Investigational Site
    Copenhagen, DK- 2100, Denmark
  • GSK Investigational Site
    Odense C, 5000, Denmark
  • GSK Investigational Site
    Bordeaux, 33076, France
  • GSK Investigational Site
    Caen, 14076, France
  • GSK Investigational Site
    Clermont-Ferrand, 63000, France
  • GSK Investigational Site
    Lille, 59000, France
  • GSK Investigational Site
    Marseille, 13273, France
  • GSK Investigational Site
    Paris, 75571, France
  • GSK Investigational Site
    Paris, 75908, France
  • GSK Investigational Site
    Saint-Herblain, 44805, France
  • GSK Investigational Site
    Villejuif, 94805, France
  • GSK Investigational Site
    Milan, 20132, Italy
  • GSK Investigational Site
    Milan, 20133, Italy
  • GSK Investigational Site
    Milan, 20141, Italy
  • GSK Investigational Site
    Modena, 41100, Italy
  • GSK Investigational Site
    Naples, 80131, Italy
  • GSK Investigational Site
    Roma, 00144, Italy
  • GSK Investigational Site
    Verona, 37134, Italy
  • GSK Investigational Site
    San Pedro Garza García, Nuevo León 66260, Mexico
  • GSK Investigational Site
    Gdynia, 81-519, Poland
  • GSK Investigational Site
    Lublin, 20-090, Poland
  • GSK Investigational Site
    Olsztyn, 10-513, Poland
  • GSK Investigational Site
    Olsztyn, 10-561, Poland
  • GSK Investigational Site
    Torun, 87-100, Poland
  • GSK Investigational Site
    Warsaw, 02-781, Poland
  • GSK Investigational Site
    Changwon, 51472, South Korea
  • GSK Investigational Site
    Gwangju, 61469, South Korea
  • GSK Investigational Site
    Seongnam-si, 463-712, South Korea
  • GSK Investigational Site
    Seongnam-si Gyeonggi-do, 463 707, South Korea
  • GSK Investigational Site
    Seoul, 02841, South Korea

Showing the first 100 of 128 sites across 13 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Patnaik A, Weiss GJ, Rasco DW, Blaydorn L, Mirabella A, Beeram M, Guo W, Lu S, Danaee H, McEachern K, Im E, Sachdev JC. Safety, antitumor activity, and pharmacokinetics of dostarlimab, an anti-PD-1, in patients with advanced solid tumors: a dose-escalation phase 1 trial. Cancer Chemother Pharmacol. 2022 Jan;89(1):93-103. doi: 10.1007/s00280-021-04358-3. Epub 2021 Nov 8. PubMed 34750637 ↗
  • Zhang XT, Chen H, Shao W, Zhongping JL, Melham M, Lu S.A Competitive Ligand Binding Assay to Measure Antidrug Antibodies Against Dostarlimab (TSR-042).2021; DOI: 10.1186/s41120-021-00039-w
  • Patterson M, Beausang LA, Rup B, Bowsher R, Krug K, Gunn G, Melham M, Lu S.A Bridging Assay for Detection and Characterization of Anti-Drug Antibodies to Dostarlimab, a New Anti-PD-1 Therapeutic Monoclonal Antibody .2021;7(11) DOI: DOI 10.1186/s41120-021-00045-y
  • Kumar S, Ghosh S, Sharma G, Wang Z, Kehry MR, Marino MH, Neben TY, Lu S, Luo S, Roberts S, Ramaswamy S, Danaee H, Jenkins D. Preclinical characterization of dostarlimab, a therapeutic anti-PD-1 antibody with potent activity to enhance immune function in in vitro cellular assays and in vivo animal models. MAbs. 2021 Jan-Dec;13(1):1954136. doi: 10.1080/19420862.2021.1954136. PubMed 34313545 ↗
  • Oaknin A, Gilbert L, Tinker AV, Brown J, Mathews C, Press J, Sabatier R, O'Malley DM, Samouelian V, Boni V, Duska L, Ghamande S, Ghatage P, Kristeleit R, Leath C III, Guo W, Im E, Zildjian S, Han X, Duan T, Veneris J, Pothuri B. Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET-a phase I, single-arm study. J Immunother Cancer. 2022 Jan;10(1):e003777. doi: 10.1136/jitc-2021-003777. PubMed 35064011 ↗
  • Kristeleit R, Mathews C, Redondo A, Boklage S, Hanlon J, Im E, Brown J. Patient-reported outcomes in the GARNET trial in patients with advanced or recurrent mismatch repair-deficient/microsatellite instability-high endometrial cancer treated with dostarlimab. Int J Gynecol Cancer. 2022 Oct 3;32(10):1250-1257. doi: 10.1136/ijgc-2022-003492. PubMed 35973737 ↗
  • Kuchimanchi M, Dabrowski C, Lu S, Melhem M. Dostarlimab, an anti-programmed death-1 monoclonal antibody, does not cause QT prolongation in patients with solid tumours: A concentration-QT analysis. Br J Clin Pharmacol. 2023 Jul;89(7):2272-2282. doi: 10.1111/bcp.15700. Epub 2023 Mar 20. PubMed 36823349 ↗
  • Andre T, Berton D, Curigliano G, Sabatier R, Tinker AV, Oaknin A, Ellard S, de Braud F, Arkenau HT, Trigo J, Gravina A, Kristeleit R, Moreno V, Abdeddaim C, Vano YA, Samouelian V, Miller R, Boni V, Torres AA, Gilbert L, Brown J, Dewal N, Dabrowski C, Antony G, Zografos E, Veneris J, Banerjee S. Antitumor Activity and Safety of Dostarlimab Monotherapy in Patients With Mismatch Repair Deficient Solid Tumors: A Nonrandomized Controlled Trial. JAMA Netw Open. 2023 Nov 1;6(11):e2341165. doi: 10.1001/jamanetworkopen.2023.41165. PubMed 37917058 ↗
  • Rodrigues M, Eberst L, Follana P, Gauthier L, Jacquemin V, Tessier C, El Mouaddin N, Boudier P, Fiteni F, Angeli E, Roche S, Delanoy N, Sabatier R, Flippot R, de la Motte Rouge T. Real-world dostarlimab use in advanced/recurrent endometrial cancer in France. Bull Cancer. 2023 Oct;110(10):1041-1050. doi: 10.1016/j.bulcan.2023.06.009. Epub 2023 Aug 31. PubMed 37659907 ↗
  • Oaknin A, Pothuri B, Gilbert L, Sabatier R, Brown J, Ghamande S, Mathews C, O'Malley DM, Kristeleit R, Boni V, Gravina A, Banerjee S, Miller R, Pikiel J, Mirza MR, Dewal N, Antony G, Dong Y, Zografos E, Veneris J, Tinker AV. Safety, Efficacy, and Biomarker Analyses of Dostarlimab in Patients with Endometrial Cancer: Interim Results of the Phase I GARNET Study. Clin Cancer Res. 2023 Nov 14;29(22):4564-4574. doi: 10.1158/1078-0432.CCR-22-3915. PubMed 37363992 ↗
  • Moreno V, Roda D, Pikiel J, Trigo J, Bosch-Barrera J, Drew Y, Kristeleit R, Hiret S, Bajor DL, Cruz P, Beck JT, Ghosh S, Dabrowski C, Antony G, Duan T, Veneris J, Zografos E, Subramanian J. Safety and Efficacy of Dostarlimab in Patients With Recurrent/Advanced Non-small Cell Lung Cancer: Results from Cohort E of the Phase I GARNET Trial. Clin Lung Cancer. 2022 Nov;23(7):e415-e427. doi: 10.1016/j.cllc.2022.05.013. Epub 2022 May 23. PubMed 35729005 ↗
  • Oaknin A, Tinker AV, Gilbert L, Samouelian V, Mathews C, Brown J, Barretina-Ginesta MP, Moreno V, Gravina A, Abdeddaim C, Banerjee S, Guo W, Danaee H, Im E, Sabatier R. Clinical activity and safety of the anti-PD-1 monoclonal antibody dostarlimab for patients with recurrent or advanced dMMR endometrial cancer. Future Oncol. 2021 Oct 1;17(29):3781-3785. doi: 10.2217/fon-2021-0598. Epub 2021 Aug 24. PubMed 34427115 ↗
  • Oaknin A, Tinker AV, Gilbert L, Samouelian V, Mathews C, Brown J, Barretina-Ginesta MP, Moreno V, Gravina A, Abdeddaim C, Banerjee S, Guo W, Danaee H, Im E, Sabatier R. Clinical Activity and Safety of the Anti-Programmed Death 1 Monoclonal Antibody Dostarlimab for Patients With Recurrent or Advanced Mismatch Repair-Deficient Endometrial Cancer: A Nonrandomized Phase 1 Clinical Trial. JAMA Oncol. 2020 Nov 1;6(11):1766-1772. doi: 10.1001/jamaoncol.2020.4515. PubMed 33001143 ↗

Individual participant data

Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.

Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.

Data sharing details ↗ · clinicalstudydatarequest.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2016 to primary completion in May 2026, 122 months.

Of 677 industry-sponsored phase 1 interventional studies under Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 62. This study's 122 months is above that.

Counting every sponsor, half of 904 studies reached it within 40 months; a quarter within 23 and three quarters within 64.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 9, 2016
First posted
Mar 22, 2016
StartActual
Mar 7, 2016
Primary completionActual
May 18, 2026
CompletionEst.
Apr 14, 2028
Last update
Aug 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 25, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02715284
Lead sponsor
Tesaro, Inc.
Responsible party
Sponsor
First posted
Mar 22, 2016
Start date
Mar 7, 2016
Primary completion
May 18, 2026
Completion
Apr 14, 2028 (estimated)
Last update
Aug 25, 2026

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dostarlimab

Start the discussion